Session 117

HR 7121

Protecting our Pharmaceutical Supply Chain from China Act of 2022

In Committee

Jurisdiction

US Congress

Session

Session 117

Official source

Chamber

House

Session

Session 117

Jurisdiction

US Congress

Bill overview

This bill, the Protecting our Pharmaceutical Supply Chain from China Act of 2022, aims to strengthen the security of the U.S. drug supply by requiring the tracking of drug origins, restricting the purchase of drugs manufactured in China by federal health programs, and ensuring drug labeling includes the country of origin for each active ingredient. It also provides tax incentives to encourage domestic manufacturing of pharmaceuticals and medical devices. The legislation seeks to reduce reliance on foreign sources, particularly China, for critical drug components.

Positions across the country

No public positions recorded for this legislation.

Arguments in favor

Reasons to support this legislation.

No arguments in favor have been submitted.

Submit yours

Arguments opposed

Reasons to oppose this legislation.

No arguments opposed have been submitted.

Submit yours

Legislative history

2022-03-17House

Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, Veterans' Affairs, and Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

2022-03-17House

Read the latest version inline or switch to a previous version.

HR 7121

Bill overview

Sponsors

Primary sponsor

Cosponsors

Positions across the country

Arguments in favor

Arguments opposed

Bill text

Positions across the country